awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9
Q38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9
A phase I study of cabozantinib (XL184) in patients with renal cell cancer.
P2860
Q38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a742793731ff159d8eb9274f3516738b313f88e4
P2860
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.